Business
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
SAN DIEGO, February 25, 2026--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously
About this update from Tandem Diabetes Care, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":221,"url":"https://media.zenfs.com/en/business-wire.com/80a4e4356fc717bc3892678a6b4f3d22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8KRYUlVkVr2W0i7Up2VrFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/80a4e4356fc717bc3892678a6b4f3d22","width":480,"height":221}},"lazy":false},{"type":"text","content":"SAN DIEGO, February 25, 2026--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $200.0 million aggregate principal amount of notes. Tandem also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $35.0 million aggregate principal amount of notes from Tandem. The sale of the notes is expected to close on February 27, 2026, subject to customary closing conditions.","length":993,"tagName":"p"},{"type":"text","content":"The notes will be general unsecured obligations of Tandem and will not bear regular interest and the principal amount of the notes will not accrete. The notes will mature on March 15, 2032, unless earlier converted, redeemed or repurchased.","length":240,"tagName":"p"},{"type":"text","content":"Tandem estimates that the net proceeds from the offering will be approximately $256.7 million (or approximately $290.7 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by Tandem. Tandem expects to use the net proceeds from the offering to pay the approximately $13.5 million cost of the capped call transactions that it entered into as described below and the remaind...